UK-based CellCentric Ltd has appointed a director of cancer biology and brought a new member onto its board of directors as the company progresses its lead drug for multiple cancer indications. Kris Frese, formerly associate scientist at Cancer Research UK, has become director of cancer biology, and Andrew Hughes, formerly of AstraZeneca Plc, has been named non-executive director. Mr Frese specialises in models of cancer and biomarker analysis. Mr Hughes led more than 50 oncology research and development programmes during his time at AstraZeneca. He is currently honorary professor of experimental cancer medicine at the University of Manchester in the UK.
CellCentric announced the appointments on 6 April 2022.
Copyright 2022 Evernow Publishing Ltd